Peroxisome proliferator-activated receptors (PPARs) are involved in the regulation of lipid and glucose metabolism. PPAR␥ agonists improve insulin sensitivity and hyperglycemia and are effective in treating type 2 diabetes mellitus (T2DM), whereas PPAR␣ agonists are used to treat dyslipidemia and atherosclerosis. The goal here was to examine the efficacy of a selective PPAR␣ agonist {(S)-3-[3-(1-carboxy-1-methyl-ethoxy)-phenyl]-piperidine-1-carboxylic acid 4-trifluoromethyl-benzyl ester; CP-900691} on lipid, glycemic, and inflammation indices in 14 cynomolgus monkeys with spontaneous T2DM maintained on daily insulin therapy. Monkeys were dosed orally with either vehicle (n ϭ 7) or CP-900691 (3 mg/kg, n ϭ 7) daily for 6 weeks. CP-900691 treatment increased plasma high-density lipoprotein cholesterol (HDLC) (33 Ϯ 3 to 60 Ϯ 4 mg/dL, p Ͻ 0.001) and apolipoprotein A1 (96 Ϯ 5 to 157 Ϯ 5 mg/dL, p Ͻ 0.001), reduced plasma triglycerides (547 Ϯ 102 to 356 Ϯ 90 mg/dL, p Ͻ 0.01), and apolipoprotein B (62 Ϯ 3 to 45 Ϯ 3 mg/dL, p Ͻ 0.01), improved the lipoprotein index (HDL to non-HDLC ratio; 0.28 Ϯ 0.06 to 0.79 Ϯ 0.16, p Ͻ 0.001), decreased body weight (p Ͻ 0.01) and C-reactive protein (CRP) (1700 Ϯ 382 to 304 Ϯ 102 ng/ml, p Ͻ 0.01), and increased adiponectin (1697 Ϯ 542 to 4242 Ϯ 1070 ng/ml, p Ͻ 0.001) compared with baseline. CP-900691 treatment reduced exogenous insulin requirements by approximately 25% (p Ͻ 0.04) while lowering plasma fructosamine from 2.87 Ϯ 0.09 to 2.22 Ϯ 0.17 mM (p Ͻ 0.05), indicative of improved glycemic control. There were no changes in any of the aforementioned parameters in the vehicle group. Because low HDLC and high triglycerides are well established risk factors for cardiovascular disease, the marked improvements in these parameters, and in glycemic control, body weight, and CRP, suggest that CP-900691 may be of benefit in diabetic and obese or hyperlipidemic populations.
al., 2000) and exhibit distinct side effect profiles (Corton et al., 2000; Willson et al., 2000; Jones, 2001; Picard and Auwerx, 2002) , there has been a focused effort in the pharmaceutical industry to develop potent PPAR agonists that exhibit a high degree of specificity for activation of individual receptor subtypes (Harwood and Hamanaka, 1998; Corton et al., 2000; Willson et al., 2000; Jones, 2001; Picard and Auwerx, 2002) .
PPAR␣, which is highly expressed in liver, skeletal muscle, and heart and activated by a variety of naturally occurring lipids and the fibrate class of dyslipidemic drugs, potentiates fatty acid oxidation and modulates lipoprotein metabolism (Corton et al., 2000; Willson et al., 2000) . Fibrates such as fenofibrate, for example, have been shown in both laboratory and clinical studies to reduce plasma triglyceride (TG) levels, reduce the number of circulating triglyceride-rich apolipoprotein B (apoB)-containing very low-density lipoprotein (VLDL) and low-density lipoprotein (LDL) particles, increase highdensity lipoprotein cholesterol (HDLC) levels through increases in apolipoprotein A1 (apoA1) production, and favorably affect atherosclerotic progression and cardiovascular outcomes (Corton et al., 2000; Faergeman, 2000; Jones, 2001; Castrillo and Tontonoz, 2004; Li et al., 2004) . Recent clinical studies evaluating chronic treatment with the PPAR␣ activators fenofibrate and bezafibrate have indeed demonstrated improvement in total, HDL, and LDL cholesterol and triglycerides, and corresponding reductions in atherosclerotic progression (Diabetes Atherosclerosis Intervention Investigators, 2001 ) and improved cardiovascular outcomes (Elkeles et al., 1998) .
Though primarily involved in lipid metabolism, PPAR␣ may also provide a link between dyslipidemia and diabetes, because T2DM patients generally also present with a variety of dyslipidemias, such as increased TG and circulating fatty acids and decreased HDLC, which further predisposes them to cardiovascular disease . In insulinresistant rodents, fibrates have been shown to decrease adiposity and improve insulin sensitivity, attenuating both hyperinsulinemia and hyperglycemia (Guerre-Millo et al., 2000) . In addition, the PPAR␣ agonist fenofibrate has been shown to lower plasma TG and LDL cholesterol concentrations, increase plasma HDLC, and ameliorate hyperinsulinemia in obese rhesus monkeys (Winegar et al., 2001 ) and elevate HDLC levels in vervet monkeys (Wallace et al., 2005) . However, supraphysiological glucose levels in vitro and hyperglycemia in vivo have been shown to attenuate PPAR␣ mRNA expression in ␤-cells and PPAR␣ expression in islets, respectively, and may negatively affect PPAR␣-related ␤-cell lipid oxidation (Roduit et al., 2000) . Furthermore, fenofibrate is not specific for PPAR␣ activation and shows a similar degree of PPAR␥ activation Jones, 2001) , thus confounding interpretation of the role of PPAR␣ agonism in glycemic regulation.
Similar to human T2DM patients, diabetic cynomolgus monkeys exhibit increased plasma concentrations of TG and VLDL cholesterol and decreased HDLC concentrations (Wagner et al., 2006) , all of which may be favorably altered by PPAR␣ activation. To determine whether pharmacologic PPAR␣ activation by highly specific PPAR␣ agonists would lead to improved insulin sensitivity and exhibit favorable effects on dyslipidemia, we have examined the effects of a highly selective PPAR␣ agonist, (S)-3-[3-(1-carboxy-1-methyl-ethoxy)-phenyl]-piperidine-1-carboxylic acid 4-trifluoromethyl-benzyl ester (CP-900691) (Hayward et al., 2006) , on lipid and glycemic indices in this clinically relevant animal model of diabetic dyslipidemia.
Materials and Methods
Characteristics of CP-900691. CP-900691 (Fig. 1) is a specific, saturable, high-affinity ligand for PPAR␣, as demonstrated in scintillation-proximity competition ligand binding assays using recombinant human PPAR␣, PPAR␤, and PPAR␥ receptor subtype ligand binding domains, where IC 50 values for PPAR␣, PPAR␤, and PPAR␥ competition with standard radiolabeled ligands averaged 12.5 Ϯ 0.4, Ͼ10,000, and 1520 Ϯ 170 nM, respectively. The 122-fold specificity relative to PPAR␥ binding and apparent lack of binding of CP-900691 to PPAR␤ was paralleled by 81-and 207-fold specificities relative to PPAR␥ and PPAR␤ activation, respectively (PPAR␣ EC 50 ϭ 22 nM, PPAR␤ EC 50 ϭ 4548 nM, and PPAR␥ EC 50 ϭ 1776 nM), in cell-based functional assays of PPAR activation (Hayward et al., 2006) . Dose Selection and Study Parameters. In selecting a dose for evaluating the actions of CP-900691 in diabetic monkeys, we compared the pharmacokinetic parameters in other species where CP-900691 reduced plasma TG in mice with an ED 30 of 0.12 mg/kg, reduced plasma TG and apoB-containing lipoprotein (VLDL ϩ LDL) cholesterol in obese dogs with an ED 40 of 1 mg/kg, and increased plasma HDLC in mice by 2.5-fold at a dose of 1 mg/kg (Hayward et al., 2006) . When pharmacokinetic parameters were assessed in the lean monkeys after a single 1 mg/kg intravenous dose and after a single 1 mg/kg oral dose, CP-900691 exhibited an oral bioavailability of 16%, a C max of 610 ng/ml at the T max of 1.8 h, a half-life of 3.8 h, a Cl p of 15 ml/min/kg, and a V diss of 1.7 L/kg. Because the bioavailability in the monkey was less than that observed in the rat and dog (16% versus 39 and 59%, respectively) and the clearance was higher in the monkey than in the rat or dog (15 versus 2.7 and 0.3 ml/min/ kg, respectively), we chose to study once-daily oral administration of 3 mg/kg/day CP-900691 for 6 weeks, an oral dose three times higher than the dose that showed efficacy in the dog studies.
Animal Protocol. Fourteen cynomolgus monkeys (Macaca fascicularis) with naturally occurring T2DM (Wagner et al., 2006) were enrolled in the study. All animals were fed a standard monkey chow diet (Purina LabDiet, Richmond, IN), divided into two meals per day, and received twice-daily insulin injections [70% intermediate-acting (e.g., NPH insulin)], 30% short-acting (i.e., regular insulin)]. Insulin doses were based on postprandial blood glucose measurements determined with a glucometer (from tail stick of conscious animals). Blood glucose concentrations were monitored by this method twice weekly, or more often if necessary, to achieve a postprandial blood glucose concentration of 100 to 200 mg/dl. Exogenous insulin requirements were recorded daily and averaged weekly for each monkey. All experimental procedures involving animals in this study were conducted in accordance with Public Health Service policy and approved by and complied with the guidelines of the Institutional Animal Care and Use Committee of Wake Forest University Health Sciences.
Monkeys were stratified into two treatment groups based, in order of priority, on sex, body weight, average daily exogenous insulin requirements, and plasma HDLC and TG concentrations determined from blood samples collected 8 weeks before dosing. Parameters (mean Ϯ S.E.M.) for vehicle control versus drug treatment groups, Two sets of baseline measurements were collected 4 and 2 weeks before dosing, followed by 6 weeks of daily dosing with either the PPAR␣ agonist CP-900691 at a dose of 3 mg/kg/day (n ϭ 7) or its vehicle (n ϭ 7). At the conclusion of dosing, the CP-900691 animals underwent 4 weeks of washout, and the control group entered into a reduced-dose crossover paradigm where the animals that received vehicle for the initial 6 weeks of dosing received 3 weeks of daily dosing with CP-900691 at the 10-fold reduced dose of 0.3 mg/kg/day.
All treatment animals were dosed orally with either vehicle or CP-900691 once a day with their afternoon feeding. The vehicle consisted of a mixture of 0.5% methocel and 0.1% Polysorbate 80. Fresh CP-900691 dosing solution was prepared each day at a concentration of 100 mg/ml. The compound was weighed and added to the vehicle, vortexed for 10 s or until thoroughly wetted, and then stirred magnetically for at least 1 h before dosing. Vehicle or drug was absorbed into a Primatreat, a piece of fruit, or other palatable treat and consumed voluntarily by each animal.
To record body weight and collect blood samples for measurement of glycemic and lipid indices, monkeys were sedated (after a 16-h fast and exogenous insulin withdrawal) with ketamine (10 -15 mg/kg i.m.), followed by supplemental maintenance doses (3-5 mg/kg i.m.) as necessary. Samples were taken at baseline, after every 2 weeks of dosing, and then 4 weeks after cessation of dosing (washout, only in animals receiving the test compound). Whole blood samples in EDTA-treated tubes were placed on ice immediately after collection and centrifuged, and the resulting plasma was removed and stored at Ϫ80°C.
Insulin tolerance tests (ITTs) were performed at week Ϫ4 (baseline) and week 4 of dosing, as described previously (Gee et al., 2004) . Two sets of baseline blood samples (Ϫ5 min and 0 min) were collected. After drawing the second baseline blood sample, regular insulin was infused at a dose of 0.2 IU/kg (0.5 ml/kg). Blood samples were subsequently collected at 3, 6, 9, 12, 15, and 20 min postinsulin. All blood samples were centrifuged, and plasma was stored at Ϫ80°C for batched analysis. Parameters measured include areas under the curve for glucose and insulin and K values for glucose disappearance rate.
Clinical Chemistry Analyses. Total plasma cholesterol was measured by enzymatic techniques based on the methods of Allain et al. (1974) . Plasma TG were determined by the methods of Fossati and Prencipe (1982) . HDLC concentrations were measured by using a slight modification (2 M MnCl 2 ) of the heparin-manganese precipitation procedure described in the Manual of Laboratory Operations of the National Heart, Lung, and Blood Institute Lipid Research Clinics Program (National Heart, Lung, and Blood Institute, 1974) . All analyses were performed on an ACE Alera Clinical Chemistry System (Alfa Wasserman, Inc., West Caldwell NJ). ApoA1, apoB, and apoCIII levels were determined by specific enzyme-linked immunosorbent assay (ELISA) as described previously (Chandler et al., 2003; Harwood et al., 2003) . The lipoprotein index was calculated as the ratio of HDLC to apoB-containing lipoprotein (VLDL ϩ LDL) cholesterol (Gotto et al., 1995) .
Plasma glucose and fructosamine concentrations were assayed by enzymatic colorimetric methods using the new glucose UV and FRUC kit (Roche Diagnostics, Indianapolis, IN). The interassay and intra-assay coefficients of variation were Ͻ5% for glucose and Ͻ10% for fructosamine. Insulin, c-peptide, and adiponectin were determined by using ELISA kits (Mercodia, Uppsala, Sweden), with Ͻ10% interassay and intra-assay coefficients of variation. Plasma C-reactive protein (CRP) was measured by using ELISA kits from ALPCO Diagnostics (Salem, NH).
Statistical Analysis. All results are reported as mean values Ϯ S.E.M. Statistical analyses were performed by using Statistica 6 (StatSoft, Tulsa, OK). Log transformation of variables was performed when normality assumptions were not met. Baseline values for lipid and glycemic variables are the average of two separate samples collected 2 and 4 weeks before dosing. Intergroup comparisons at baseline were performed by using one-way ANOVA. Comparisons of glycemic and lipid variables at subsequent time points were made by using repeated measures ANOVA. ITT parameters at 4 weeks of treatment were analyzed by analysis of covariance, with baseline values serving as covariates. Tukey HSD post hoc tests were performed to identify specific intragroup or intergroup differences when ANOVA/analysis of covariance p Ͻ 0.05.
Results
A comparison of the mean baseline values of the lipid and glycemic parameters and of CRP and adiponectin for the vehicle-treated and CP-900691-treated cohorts at the beginning of the study is shown in Table 1 .
Plasma Lipid and Lipoproteins. Total TG were lowered significantly (p Ͻ 0.05 versus baseline) at 2, 4, and 6 weeks with CP-900691 treatment, with no change in plasma TG levels in the vehicle-treated group ( Fig. 2A) . CP-900691 treatment also significantly decreased plasma apoB levels at every time point evaluated relative to both baseline (p Ͻ 0.05) and vehicle-treated control animals (p Ͻ 0.05) (Fig. 2B) , suggesting a reduction in the number of apoB-containing lipoproteins. Both plasma VLDL and LDL cholesterol were decreased in a time-dependent manner with CP-900691 treatment, attaining significance compared with baseline after 4 weeks of treatment [LDL cholesterol, 32 .2% reduction (55.4 Ϯ 3.6 versus 81.7 Ϯ 8.4 mg/dl), p Ͻ 0.05; VLDL cholesterol, 34.4% reduction (34.1 Ϯ 12.3 versus 52.0 Ϯ 18.2 mg/dl), p Ͻ 0.05)] and remaining similarly decreased after 6 weeks of treatment, with no time-dependent change in either parameter in the vehicle-treated group. Plasma TG, apoB, and LDL cholesterol levels all returned to baseline values within 4 weeks of cessation of treatment with CP-900691 (Fig. 2) .
Even though there was a marked reduction in plasma TG and plasma apoB-containing lipoprotein cholesterol levels in response to treatment with CP-900691, total plasma cholesterol was unchanged by treatment with either vehicle or CP-900691 (data not shown). The absence of a notable change in total cholesterol concentration even though plasma LDL and VLDL cholesterol were markedly reduced was a consequence of a dramatic, up to 2.2-fold, increase in plasma HDLC concentration (Fig. 3A) , which increased from 33 Ϯ 3 to 65 Ϯ 3 mg/dL after only 2 weeks of dosing with CP-900691 and remained similarly elevated throughout the 6-week dosing interval (p Ͻ 0.05 versus baseline), with no change in plasma HDLC levels in the vehicle-treated group. Because the HDL-elevating effect of PPAR␣ agonism by fibrates is caused, in part, by receptor-mediated up-regulation of apoA1 production (Harwood and Hamanaka, 1998; Willson et al., 2000) , we evaluated the effects of CP-900691 on plasma apoA1 concentrations. Similar to the effects of CP-900691 treatment on HDLC levels, plasma apoA1 concentrations were also increased after CP-900691 treatment relative to baseline and vehicle controls after 2 weeks of dosing and remained significantly elevated throughout the course of the study (Fig. 3B) . Plasma HDLC and plasma apoA1 levels both returned to baseline values within 4 weeks of cessation of treatment with CP-900691.
The lipoprotein index is commonly used to assess the potential cardiovascular risk associated with various distributions of cholesterol between the lipoprotein subclasses among individuals where a high lipoprotein index is considered more favorable than a lower lipoprotein index (Gotto et al., 1995) . As shown in Fig. 4 , the lipoprotein index remained constant at approximately 0.6 throughout the course of the study in the vehicle-treated cohort, but increased approximately 2.5-fold within the first 2 weeks of treatment with CP-900691 and remained elevated at that level throughout the 6 weeks of treatment. The lipoprotein index returned to near background within 4 weeks of cessation of treatment, consistent with the time course of return to baseline of plasma TG, apoB-containing lipoproteins, and HDLC concentrations (see above).
Changes in Insulin Requirements and Glycemic Measures. Insulin requirements for monkeys in the vehicle group remained unchanged throughout the 6-week study period, whereas daily insulin needs in the CP-900691 monkeys declined significantly by the 3rd week of jpet.aspetjournals.org dosing and remained markedly diminished (p Ͻ 0.05 versus baseline) at every time point from weeks 3 through 6 of treatment (Fig. 5) . After cessation of treatment, the rebound in insulin requirement was slow relative to the return to baseline observed for the lipid parameters (see above). Indeed, the requirement for exogenous insulin continued to decline during the first 2 weeks of washout and thereafter increased by only 10% from the nadir mean insulin requirement noted 1 week after cessation of treatment.
To demonstrate the accuracy with which adjustments in exogenous insulin requirements were made temporally during the course of treatment with CP-900691, plasma fructosamine concentrations were measured. Similar to the use of glycated hemoglobin levels as a marker of long-term glycemic status, changes in plasma fructosamine levels are a sensitive marker of changes in short-term glycemic control (Cefalu et al., 1993) . Figure 6 illustrates a time-dependent reduction in fructosamine levels in the CP-900691-treated cohort such that plasma fructosamine levels were significantly lower than baseline (p Ͻ 0.05) after 6 weeks of treatment. These observations, together with the sustained reduction in exogenous insulin requirements, are indicative of a long-term improvement in glycemic control by treatment with CP-900691.
There were no differences in fasting glucose or insulin levels between the vehicle-and CP-900691-treated cohorts (Table 2 ). This is likely caused by the monitoring and adjustment in exogenous insulin administration throughout the course of study. In addition, there were no differences in mean C-peptide levels between control and treated cohorts throughout the course of the study (Table 2) , consistent with the reduced capacity for glucose-stimulated insulin secretion in these animals (Wagner et al., 2006) .
To determine whether the reductions in exogenous insulin requirements and fructosamine concentrations were the result of improvements in insulin sensitivity resulting from treatment with CP-900691, ITTs were conducted at baseline and after 4 weeks of treatment. Calculated areas under the curves for ITT at each time point, along with the respective K values for glucose disappearance rate, are presented in Table  3 . CP-900691 did not alter areas under either the glucose or insulin curves compared with vehicle-treated controls. Similarly, treatment with CP-900691 did not significantly alter the slopes of the glucose disappearance curves (K g ) compared with either K g values obtained at baseline or K g values ob- Body Weight Reduction. There was no significant difference in average body weight between the vehicle-and CP-900691 treated animals at baseline (8.7 Ϯ 1.0 versus 10.6 Ϯ 0.6 kg, p ϭ 0.21). Although food consumption was observed to be normal for all animals, there was a significant, time-dependent reduction in overall body weight in the animals receiving CP-900691 treatment relative to baseline measurements (Fig. 7) , with CP-900691 treatment leading to significant reductions after 4 weeks (Ϫ4.4 Ϯ 1.3%) and 6 weeks (Ϫ5.7 Ϯ 1.5%) of treatment (both p Ͻ 0.05 versus baseline). Body weight remained unchanged in the vehicle group over the course of the study. In addition, similar to the slow rebound of exogenous insulin requirements after cessation of CP-900691 treatment (see above), mean body weight in the CP-900691 cohort continued to decline slightly for the first 4 weeks of washout and did not return to baseline within the duration of the study.
Improved CRP and Adiponectin. Biomarkers of inflammation were improved with plasma CRP concentrations reduced by 68% after 2 weeks of treatment with CP-900691 and sustained reductions throughout the 6 weeks of treatment with a return to baseline after 4 weeks of washout (Fig. 8A) . In contrast, plasma adiponectin, a fat-derived hormone, produced in an inverse relationship with the amount of fat stores (Picard and Auwerx, 2002) , was increased by 55% after 2 weeks of treatment with CP-900691 and continued to increase to over 300% of baseline after 6 weeks of treatment, before returning toward baseline values after 4 weeks of washout (Fig. 8B) .
Reduced Dose Crossover Study. The observation that the highly selective PPAR␣ agonist CP-900691, at 3 mg/kg, favorably affected glycemic control in addition to its beneficial effects on the dyslipidemia in these diabetic monkeys, suggests that PPAR␣-specific receptor agonism may be capable of favorably affecting glycemic control independent of concomitant PPAR␥ agonism. Although CP-900691 demonstrated an approximately 122-fold specificity for PPAR␣ over PPAR␥, the peak plasma concentration of CP-900691 in the diabetic monkeys at the 3.0 mg/kg dose evaluated (1.31 nM) was only slightly less than the IC 50 values obtained in the competition binding assay for CP-900691 association with PPAR␥ (1.52 nM) and the EC 50 values obtained for PPAR␥ functional agonism of CP-900691 in cultured cells (1.78 nM). This suggests that at least for a short time after each dose there was sufficient CP-900691 in the plasma of the treated monkeys to partially activate PPAR␥.
To determine whether partial, short-term PPAR␥ agonism was responsible for the improvements in glycemic control reported above, at the conclusion of the above study, animals were subjected to a reduced dose crossover paradigm whereby the animals that received vehicle for the initial 6 weeks of dosing received 3 weeks of daily dosing with CP-900691 at a 10-fold reduced dose of 0.3 mg/kg/day, a dose for which peak plasma levels of CP-900691 (61 ng/ml) were 11.8-fold less than those required to activate PPAR␥, followed by 4 weeks of washout. After 3 weeks of treatment with 0.3 mg/kg CP-900691, plasma TG concentrations were reduced by 39% (p Ͻ 0.05; six of seven animals responding), plasma HDLC was increased by 24% (p ϭ 0.008; five of seven animals responding), exogenous insulin requirement was reduced by 23% (p ϭ 0.02; five of seven animals responding), adiponectin levels were increased by 37% (p ϭ 0.006; seven of seven animals responding), CRP levels were reduced by 68% (p ϭ 0.02; seven of seven animals responding), and body weight was reduced by 3.6% (p ϭ 0.004; seven of seven animals responding) compared with baseline (Table 4) ; suggesting beneficial effects of CP-900691 were mediated by PPAR␣ agonism.
Discussion
The hallmark of PPAR␣ agonism is its ability to reduce plasma triglycerides and apoB-containing lipoproteins (VLDL and LDL) and elevate plasma HDLC concentrations (Gotto et al., 1995; Harwood and Hamanaka, 1998; Faergeman, 2000; Willson et al., 2000) . For this reason fibrates have broad appeal for treating a variety of dyslipidemias, including diabetic dyslipidemia (Gotto et al., 1995; Harwood and Hamanaka, 1998; Willson et al., 2000) . Although several fibrates have shown improvements in insulin sensitivity and glycemic control in addition to benefits on dyslipidemia (Guerre-Millo et al., 2000; Winegar et al., 2001 ), these fibrates show little specificity for activation of PPAR␣ relative to activation of PPAR␥ (Harwood and Hamanaka, 1998; Corton et al., 2000; Willson et al., 2000) , which precludes an estimation of the impact of PPAR␣ agonism on glycemic control per se. To evaluate the effects of PPAR␣ agonism on insulin sensitivity and glycemic control we studied the actions of a highly selective PPAR␣ agonist, CP-900691, on the lipid and glycemic indices of T2DM monkeys.
CP-900691 demonstrated effects consistent with PPAR␣ agonism. In vitro, CP-900691 has 120-fold specificity for PPAR␣ relative to PPAR␥ and a more than 10,000-fold specificity relative to PPAR␤, with respect to both competition ligand binding and functional receptor activation (Hayward et al., 2006) . Reported here, CP-900691 markedly reduced plasma triglycerides and apoB, reduced apoB-containing lipoproteins, markedly elevated HDLC and apoA1 concentrations, and improved the lipoprotein index (HDL to non-HDLC ratio). CRP, a sensitive proinflammatory biomarker, was also decreased. These beneficial changes all occurred rapidly, demonstrating maximal effects within 2 weeks of treatment and maintaining achieved levels of efficacy throughout the 6-week course of study, similar to the time course of efficacy onset noted in clinics for beneficial effects of fibrates on dyslipidemia (Corton et al., 2000; Willson et al., 2000; Jones, 2001; Castrillo and Tontonoz, 2004) . Furthermore, the lipid, lipoprotein, and CRP changes induced by CP-900691 all returned to baseline within 4 weeks after cessation of treatment, indicative of a primary effect of the compound on these parameters. CP-900691 also improved glycemic control. Unlike the rapid onset of maximal changes and rapid return to baseline after cessation of treatment in plasma lipoproteins and CRP, the reduction in exogenous insulin requirements in response to CP-900691 treatment was slower in onset and sustained even after cessation of treatment. In addition to the decrease in insulin requirements, there was a significant reduction in plasma fructosamine, a surrogate indicator of glycemic control (Cefalu et al., 1993) . Similarly, adiponectin, a marker of reduced adipose mass, reduced inflammation, and improved insulin sensitivity (Fernandez-Real et al., 2003; Tan et al., 2004) , increased across the 6-week treatment period, also consistent with a secondary effect of CP-900691 action. The improvements in glycemic status, however, were not a direct consequence of increased peripheral insulin sensitivity, because the rate of glucose disappearance from ITTs, which is mediated primarily by muscle, was not different between control and CP-900691-treated animals. Effects on hepatic insulin sensitiv- ity were not determined and may likely have been improved secondarily to the improved hepatic lipoprotein metabolism. In addition to benefits on dyslipidemia and glycemic control, CP-900691 significantly reduced overall body weight. The reduction in body weight followed a time course similar to that noted for reduction in exogenous insulin requirement, exhibiting a slow onset, a steady decline through the course of study, and a continual decrease even after treatment cessation. Like the requirements for exogenous insulin, the slow onset and sustained reduction in body weight are suggestive of secondary effects of PPAR␣ agonism.
Whether the reduction in insulin requirement and concomitant reduction in insulin-mediated weight gain was responsible for the overall body weight reduction noted in these animals or whether a PPAR␣-agonism mediated reduction in body weight was responsible for the reduced insulin requirement of these animals is uncertain. However, it is clear from the reduced dose crossover data and the lack of weight gain in the CP-900691-treated animals [weight gain is a hallmark of PPAR␥ activation in clinic Picard and Auwerx, 2002) and no weight reduction was found in T2DM monkeys treated with the PPAR␥-specific agonist, rosiglitazone (Gee et al., 2004) ], that these effects are likely mediated primarily through PPAR␣ agonism rather than through PPAR␥ agonism, because effects persisted even when the dose of CP-900691 was reduced to a level where the potential for concomitant PPAR␥ activation was negligible (C max levels 11.8-fold lower than the EC 50 for PPAR␥ activation).
Changes in markers of inflammation were also improved in these monkeys, consistent with other studies suggesting that PPAR␣ agonism also reduces the proinflammatory state associated with diabetes, obesity, and cardiometabolic syndrome Li et al., 2004) . Reductions in CRP occurred rapidly, demonstrating maximal effects within 2 weeks of treatment and maintaining achieved levels of efficacy throughout the 6-week treatment. By contrast, adiponectin concentrations exhibited a steady increase throughout the study. These observations are in stark contrast to alterations in CRP and adiponectin noted in these animals after treatment with the PPAR␥-specific agonist, rosiglitazone, where adiponectin levels were rapidly elevated to maximal levels within 2 weeks of treatment and were maintained at those elevated levels for the remainder of treatment, and where CRP levels were only marginally decreased (Gee et al., 2004; Wagner et al., 2006) . Furthermore, when the dose of CP-900691 was reduced, decreases in CRP and increases in adiponectin after CP-900691 treatment persisted further, suggesting that these effects are likely both mediated primarily through selective PPAR␣ agonism.
The differential effects of CP-900691 and rosiglitazone on CRP and adiponectin may also serve to underscore fundamental differences in the actions of PPAR␣ and PPAR␥ agonism. For example, a central role of the adipose tissue in the effects of PPAR␥-activating drugs, such as rosiglitazone, on glucose homeostasis has been well established (Picard and Auwerx, 2002) . The rapid and sustained increase with rosiglitazone treatment of adiponectin, a cytokine of adipocyte origin whose gene is under the positive control of a PPAR␥ response element (Combs et al., 2002) , is not surprising and is likely a primary effect of the drug. By contrast, the primary site of action of PPAR␣ agonists, like CP-900691, is the liver (Corton et al., 2000 ; Willson et al., 2000) , and it is believed that increases in adiponectin produced by PPAR␣ agonists occur secondary to reduced weight loss and adipose tissue mass and likely improved hepatic insulin action (Yang et al., 2001) . The pattern of adiponectin increase observed after CP-900691 treatment, which developed slowly relative to changes in lipid metabolism and CRP levels and more closely paralleled the weight reduction induced by the compound, is consistent with this hypothesis.
The rapid and sustained decrease of CRP in response to CP-900691 treatment, which paralleled the time course of modulation of lipid metabolism, is not surprising and is likely a primary effect of the drug because CRP is produced by the liver and is under direct negative control by PPAR␣ agonists . By contrast, changes in CRP in response to PPAR␥ agonism occur as a secondary response to reductions in tumor necrosis factor ␣, an adipocyte-derived signaling molecule (Picard and Auwerx, 2002 ) that controls CRP expression in the liver and whose expression is blunted by PPAR␥ agonists Picard and Auwerx, 2002; Gee et al., 2004) . That rosiglitazone, the highly selective PPAR␥ agonist, showed no changes in tumor necrosis factor ␣ and only small reductions (approximately 20 -25%) in CRP (Gee et al., 2004; Wagner et al., 2006) is consistent with the secondary nature of this action.
The differences in the responses of CRP and adiponectin to CP-900691 and rosiglitazone treatment further support the suggestion that the actions of CP-900691 reported here are primarily the result of PPAR␣ activation by the compound rather than a composite of concomitant PPAR␣ and PPAR␥ activation. However, it should be noted that the possibility exists for altered PPAR␥ sensitivity to drug actions or elevated drug concentrations to occur in specific target tissues that could potentially result in PPAR␥ activation in those tissues at plasma drug concentrations that would theoretically preclude PPAR␥-mediated contributions to efficacy. Therefore the role of PPAR␥ activation in the favorable actions of CP-900691 on glycemic control cannot be entirely ruled out. Studies in knockout mouse models would be needed to definitively address this.
In conclusion, one unifying aspect of the pharmacology of the plethora of PPAR agonists that have been developed over the past decade that has remained a verity is that each agonist exhibits a distinct profile of activation of the three classes of PPARs, and as a consequence, each exhibits a somewhat distinct efficacy profile with respect to modulation of lipid and carbohydrate metabolism and a distinct safety profile. In this article, we describe the efficacy profile of a highly PPAR␣-specific PPAR agonist that demonstrates favorable effects on dyslipidemia and glycemic control, body weight, and inflammation in T2DM monkeys. Whether such an efficacy profile for CP-900691 would translate to human T2DM patients with associated diabetic dyslipidemia and whether similar efficacy would also be observed in obese nondiabetic patients or patients with cardiometabolic syndrome remains to be determined.
